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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Although global and Asian studies on second-line pemetrexed for the
treatment of advanced nonsmall cell lung cancer have confirmed its efficacy and safety,
a pivotal postcommitment study to consolidate the evidence regarding the Taiwanese popula-
tion was warranted. This open-label single-arm study assessed the objective response rate to
a tailored dose of single-agent pemetrexed in Taiwanese patients with advanced nonsmall cell
lung cancer who had received prior chemotherapy.
Methods: Patients with stage IIIB/IV disease were treated with pemetrexed on day 1 of each
21-day cycle. A 500 mg/m2 dose was administered in cycle 1. For cycle 2, the dose wasEmerging Markets Business Unit (EMBU), Eli Lilly and Company, Fu-Hsing North Road, Taipei 105,
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Pemetrexed in nonsmall cell lung cancer 519increased to 1000 mg/m2 (if there was no toxicity above predefined levels) or decreased to
375 mg/m2. All patients received standard supplemental therapy. Patient follow-up continued
until 18 months after the last patient was enrolled in this study or death. All patients were
included in all analyses.
Results: Of the 33 patients who were enrolled, 25 (75.8%) received the 1000 mg/m2 dose
during cycle 2; 18 patients were dropped from the study, including 17 (51.5%) who had died
by the time of analysis. The objective response and disease control rates were 18.2% (95%
confidence limits [CI]: 7.0e35.5) and 54.5% (95% CI: 36.4e71.9), respectively. No patients ex-
hibited a complete response. There were two serious drug-related adverse events (neutrope-
nia and leukopenia) and two drug-related adverse events that resulted in removal from the
study. Decreased neutrophil/granulocyte counts were the most frequently observed drug-
related grade 3/4 events (9 patients, 24 treatment cycles).
Conclusion: The objective response rate, disease control rate, and safety and tolerability
profile in this population of Taiwanese patients were consistent with the published findings
that were conducted using Asian and Western populations. These findings support the use of
single-agent, second-line pemetrexed for the treatment of advanced nonsmall cell lung cancer
in Taiwanese patients.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
The incidence of lung cancer is increasing in Taiwan1 and
other Asian countries.2 In 2007, lung cancer was the leading
cause of cancer death in Taiwan with a mortality rate of
34.9 per 100,000 persons.1 Nonsmall cell lung cancer
(NSCLC) is the most common form of lung cancer, and the
majority of patients present with advanced disease3 and
have a poor clinical prognosis.4 Despite advancements in
first-line therapy, the majority of patients relapse5 and
require alternative second-line therapies.
Clinical studies have shown that patients with relapsed
NSCLC can achieve clinically meaningful increases in
survival with second-line therapy.6e8 Docetaxel was the
first chemotherapeutic agent approved for this setting.6,8
However, the findings of phase III clinical trials suggest
that patients treated with docetaxel demonstrate only
modest response rates,6,8 but investigations into other
suitable second-line therapies have continued. Peme-
trexed, a multitargeted antifolate, has been approved for
use as a single-agent in second-line therapy9 and in
combination with cisplatin for first-line therapy10 for
treating locally advanced or metastatic NSCLC. Findings
from a phase III, multinational, randomized, controlled trial
demonstrate that second-line pemetrexed has a compa-
rable efficacy and a more favorable toxicity profile in
comparison with docetaxel.7 Given the typically poor
prognosis of advanced NSCLC in this study, the improved
toxicity profile of pemetrexed over docetaxel is clinically
relevant due to its enhanced tolerability in patients. Since
this first study, several other late-phase studies have
confirmed the efficacy and safety of single-agent peme-
trexed when used as a second-line therapy in Western
populations11,12; however, evidence among specific Asian
populations is somewhat limited.
At the time this study was conducted, the recommended
dose for pemetrexed was not confirmed. In addition, several
clinical studies had confirmed increased tolerability to
pemetrexed treatment when patients receive supplemental
folic acid and vitamin B12. Therefore, the primary objectiveof this study was to determine the objective response rate to
single-agent pemetrexed when used at tailored dosing when
supplemented with folic acid and vitamin B12 in Taiwanese
patients with advanced NSCLC who had received prior
chemotherapy. The secondary objectives were to evaluate
the overall survival rate, disease control rate, and time-to-
event efficacy variables and to characterize the toxicity
profile of pemetrexed in this patient population.Patients and methods
Study design
This phase IV, multicenter, open-label, single-arm study
was conducted between November 2006 and November
2009 at four sites in Taiwan. The study was conducted in
accordance with the Declaration of Helsinki, the Interna-
tional Conference on Harmonisation Guidelines for Good
Clinical Practice, and local regulations. Appropriate insti-
tutional ethics committee approval was obtained before
the study commenced (protocol no. H3E-MC-JMIC). All
patients gave voluntary, signed, informed consent before
any study-related procedures were administered. This trial
is registered with ClinicalTrials.gov (registration no.
NCT00380718).
Study population
The main inclusion criteria consisted of the following: age
over 18 years; measurable (as determined by Response
Evaluation Criteria in Solid Tumors [RECIST criteria]13),
locally advanced, or metastatic, stage IIIB or IV, histologi-
cally or cytologically diagnosed NSCLC; disease progression
following one prior chemotherapeutic regimen for pallia-
tion with or without subsequent targeted biological
therapy; Eastern Cooperative Oncology Group (ECOG)
scale14 performance status of 0e1; and willingness to
provide written informed consent. The main exclusion
criteria included the following: patients who had previously
520 G.-C. Chang et al.completed or withdrawn from another investigational study
on pemetrexed; patients with known or suspected brain
metastasis or a neurological or mental disorder; and
concurrent administration of any other tumor therapy.Treatment protocol
Pemetrexed (Eli Lilly and Company, Indianapolis, IN) was
administered as an intravenous infusion (in 75e125 mL of
0.9% sodium chloride) on day 1 of each 21-day cycle. For
cycle 1, the pemetrexed dose was 500 mg/m2. The dose
was increased to 1000 mg/m2 in cycle 2 if the patient
demonstrated no predefined toxicity in cycle 1 (see
Appendix I for details regarding predefined toxicity). During
cycle 1, all patients demonstrating hematological or non-
hematological toxicities above predefined levels had their
pemetrexed dose reduced to 375 mg/m2 in cycle 2.
A maximum number of cycles was not defined in this study.
Study treatment continued until a patient met any of the
following criteria: evidence of progressive disease; addi-
tional tumor treatments were required; unacceptable
toxicity; the patient was unable to receive the study drug
for 42 days since the last pemetrexed administration; or the
patient had completed six cycles of therapy and the
investigator considered discontinuation to be in the best
interest of the patient. Efficacy assessments were repeated
approximately every 6e8 weeks until documented disease
progression, death, or 18 months after study enrollment,
whichever occurred first. Patients with documented disease
progression were monitored for survival approximately
every 3 months until death or until 18 months after the last
patient was enrolled in the study, whichever occurred first.
Supplemental treatment
Supplementation with folic acid (oral daily doses of
350e600 mg or equivalent) and vitamin B12 (intramuscular
injection of 1000 mg administered every 9 weeks) began 1e2
weeks before cycle 1 and continued until 3weeks after the last
cycle. All patients received dexamethasone (4 mg oral dose or
equivalent administered twice daily) the day before, the day
of, and the day after each pemetrexed treatment cycle.
Study assessments
Assessments included medical history, physical examination,
vital signs, ECOG performance status, toxicity rating,
concomitant medication, and hematological and blood
chemistry analyses. Assessments were conducted at baseline
and were repeated for each cycle and at the first posttherapy
visit (within 30 days of last dose). Baseline tumor size was
determined using a computed tomography (CT) scan and/or
chest X-ray, and tumor measurements were repeated
approximately every6weeks (except in thecaseof a complete
or partial response, in which case confirmation of response
was required 4e5weeks after the first documented response).
The frequency of thymidylate synthase (TS) and methyl-
enetetrahydrofolate reductase (MTHFR) polymorphisms in
each patient’s white blood cell DNAweremeasured. Tumor TS
and MTHFR polymorphisms were not examined in this study.
Nucleotide sequence analysis was performed by Vita Geno-
mics Inc. (Taipei, Taiwan) using an ABI 3700 high-throughput
DNA sequencer (Applied Biosystems, Foster City, CA), as perthe manufacturer’s instructions. Prior to sequencing, TS and
MTHFR DNA were amplified by polymerase chain reaction
using AmpliTaq Gold DNA polymerase (Applied Biosystems,
Foster City, CA) and proprietary primer sequences (Vita
Genomics). Postamplification mixtures were treated using
Exo-SAP IT clean-up kits (USB Products, Affymetrix, Inc.,
Cleveland, Ohio), as per the manufacturer’s instructions.
Outcome measures
Primary outcome measures
The primary outcome measure of efficacy was the objective
response rate, which was defined as the number of patients
with a documented and confirmed response (complete or
partial response) divided by the number of patients eligible
for tumor response analysis.
Secondary outcome measures
Efficacy
The secondary outcome measures of efficacy were the
overall survival rate, disease control rate, progression-free
survival time, duration of response of the responding
patients, and time-to-treatment failure. Overall survivalwas
defined as the time from study enrollment until the time of
death due to any cause. For patients who were still alive at
the time of analysis, survival time was censored at the last
follow-up visit. The disease control rate was defined as the
number of patients with a documented and confirmed
complete response, partial response, or stable disease
divided by the number of patients eligible for tumor response
analysis. Progression-free survival time was defined as the
time from enrollment to objective disease progression or
death, whichever occurred first. The duration of response
was defined as the first documentation of a complete or
partial response until progression-free survival. Time-to-
treatment failure was define as the time from enrollment to
treatment discontinuation due to undocumented progres-
sion, toxicity, other reason, or commencement of new
anticancer treatment, and patients who were still partici-
pating in the study without treatment failure at the time of
analysis were censored at the last tumor assessment.
Safety and tolerability
The secondary safety and tolerability outcome measure was
the quantitative and qualitative toxicity of pemetrexed. The
incidence of adverse events (AEs), laboratory changes, and
serious adverse events (SAEs) that occurred during the
treatment period or within 30 days of the last dose of study
treatment were recorded regardless of causality. Adverse
events were categorized according to the Medical Dictionary
for Regulatory Activities (MedDRA, version 11)15, and labo-
ratory and nonlaboratory events were categorized according
to the maximum Common Terminology Criteria for Adverse
Events (CTCAE, version 3.0)16 grading scale.
Statistical analysis
The sample size of at least 30 patients was based on the
minimum regulatory requirements Taiwan Food and Drug
Administration (TFDA). The efficacy and safety analysis
Figure 1 Patient flow diagram. A total of 33 Taiwanese
patients were enrolled in this study and were included in the
analysis for efficacy and safety. NZ total number of patients;
n Z number of patients.
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study and received more than one dose of study drug. Data
were analyzed when the last enrolled patient had received at
least six cycles of pemetrexed. Demographic and safety data
were summarized by presenting the frequency distributions
and/or descriptive summary statistics (e.g., mean, standard
deviation, median, minimum, and maximum). For efficacy
analyses, estimates of the exact (95% confidence limits [CLs])
objective response rate and disease control rate were calcu-
lated. Kaplan-Meier summary statistics17 were provided for
overall survival, duration of response of the responding
patients, and each of the time-to-event outcomes. Kaplan-
Meier summary statistics were not calculable (NC) for some
variablesbecause thecurvedidnot reach the specified timeor
percentile. Additional exploratory analyses for prognostic
factors, including histological type (squamous vs. non-
squamous), sex (male vs. female), dose escalation at cycle 2
(escalated vs. nonescalated), and smoking status (smoker vs.
nonsmoker)were performed for the best overall response and
grade 3/4 CTCAE events. Comparisons were made using the
Fisher exact test; however, the outcomes of these analyses
were deemed exploratory due to the small sample size.
Missing data were not included in the analysis. For all anal-
yses, two-sided comparisons were made and the statistical
significance was set at p  0.05. Statistical analyses were
conducted using SAS (version 9.1.3; SAS, Cary, NC, USA).
Results
Patient disposition
A total of 33 patients were enrolled in the study and 15
(45.5%) patients completed the study follow-up period
(Fig. 1). All patients discontinued study therapy, most
commonly because of an inadequate response, as defined
by evidence of progressive disease or the need for addi-
tional antitumor therapy (20 patients; 60.6%). Of the 33
patients enrolled, 18 discontinued the study, including 17
patients (51.5%) who died by the time of analysis. All
subjects were included in the efficacy and safety analyses.
Demographic data and baseline characteristics
The patients demonstrated a median age of 56.7 years
(range: 39e85 years; Table 1) and 60.6% were male. Most
patients (90.9%) had stage IV disease on enrollment. All 33
patients had undergone prior chemotherapy that included
cisplatin (28 patients; 84.8%), gemcitabine (25 patients;
75.8%), carboplatin or paclitaxel (4 patients each; 12.1%),
or docetaxel (3 patients; 9.1%). Other treatments included
immunological or biological therapy (12 patients; 36.4%),
radiotherapy (4 patients; 12.1%), or surgery (2 patients;
6.1%). The most common genotypes for white blood cell
DNA TS and MTHFR were 3R/3R (21 patients; 67.7%) and
cytosine/thymine (17 patients; 54.8%), respectively.
Duration of pemetrexed treatment
Most patients were able to receive an increased dose during
cycle 2, with 25 patients (75.8%) receiving the 1000 mg/m2dose. A total of 196 treatment cycles were administered
during the study. The median number of cycles received per
patient was 4 (mean: 5.9 cycles; range: 1e17 cycles) and
the median weekly pemetrexed dose intensity was
251.5 mg/m2/week (range: 125e323 mg/m2/week). The
patients received a median 99.3% (range: 75e101%) of the
planned mean dose. The pemetrexed dose was reduced in
six patients (18.2%; due to adverse events) and/or delayed
in 16 patients (48.5%; due to scheduling conflicts or adverse
events).Efficacy
The objective response rate was 18.2% (95% CL: 7.0e35.5)
and the disease control rate was 54.5% (95% CLs:
36.4e71.9). Six (18.2%), 12 (36.4%), and 11 (33.3%) patients
Table 1 Baseline demographics and disease characteristics of Taiwanese patients with nonsmall cell lung cancer.
Characteristic Enrolled patients
N Z 33
Male, n (%) 20 (60.6)
Median age, (range), y 56.7 (39e85)
Smoker, n (%) 20 (60.6)
ECOG status, n (%)
0 9 (27.3)
1 24 (72.7)
Disease stage at study entry, n (%)
IIIB 3 (9.1)
IV 30 (90.9)
Pathological diagnosis, n (%)a
Adenocarcinoma of the lung 23 (69.7)
Large cell carcinoma of the lung 1 (3.0)
Squamous cell carcinoma of the lung 8 (24.2)
Nonsmall cell carcinoma of the lung 1 (3.0)
Median time from initial diagnosis to study entry, mo (range) 7.6 (2.1e126.1)
Median time from prior chemotherapy failure to study entry, mo (range)b 0.9 (0.4e2.4)
Median time from initial diagnosis to prior chemotherapy failure, mo (range)b 7.2 (1.6e124.8)
Median homocysteine, mmol/L (range)c 6.9 (3.5e16.2)
Median 24-h creatinine clearance, mL/min (range) 76.8 (44.1 - 155.4)
TS genotype (5’UTR-2R/3R), n (%)d
2R/2R 1 (3.2)
2R/3R 9 (29.0)
3R/3R 21 (67.7)
MTHFR genotype (C677T), n (%)d
C/C 13 (41.9)
C/T 17 (54.8)
T/T 1 (3.2)
5’UTR-2R/3RZ white blood cell DNA TS polymorphisms in the 5’-untranslated region where there were either 2 or 3 tandem repeats per
allele (2R or 3R); C677T Z white blood cell DNA MTHFR polymorphisms where there is either a cytosine or thymine residue at position
677 of the gene (C or T); ECOGZ Eastern Cooperative Oncology Group; NZ total number of patients; nZ number of patients; MTHFRZ
methylenetetrahydrofolate reductase; TS Z thymidylate synthase.
a Pathological and diagnostic definitions: adenocarcinoma Z malignant epithelial tumor with glandular differentiation; large cell
carcinoma Z an undifferentiated nonsmall cell carcinoma; squamous cell carcinoma Z malignant epithelial tumor showing keratini-
zation and/or intercellular bridges; nonsmall cell carcinoma Z nonsmall cell carcinoma not otherwise specified.
b Data not available for 8 patients.
c The baseline total homocysteine (tHcy) level was measured before folic acid and vitamin B12 supplementation was administered.
After baseline, the serum tHcy level was always measured before the pemetrexed dose was given, first on day 1 of cycle 3 and then every
3 cycles thereafter.
d Data not available for 2 patients.
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progressive disease, respectively. No patients demon-
strated a complete response.
The median (95% CL) overall survival rate was 20.2
months (11.8eNC) and the 6- and 12-month (95% CL)
survival probabilities were 78.1% (59.5e88.9) and 65.5%
(46.4e79.2), respectively (Fig. 2A). The median (95% CL)
progression-free survival rate was 6.9 months (3.0e9.5)
and the 6-month progression-free survival probability was
54.7% (33.0e72.0). The 12-month progression-free survival
probability was NC (Fig. 2B). The median (95% CL) time-to-
treatment failure was 2.9 months (1.7e4.9), and the 6-
and 12-month (95% CL) time-to-treatment failure proba-
bilities were 33.3% (18.2e49.3) and 6.1% (1.1e17.6),respectively (Fig. 2C). The median (95% CL) response
duration was 6.6 months (4.2eNC) and the 6-month
duration of response probability was 62.5% (14.2e89.3).
The 12-month duration of response probability was NC
(Fig. 2D).Safety and tolerability
The majority of patients were able to tolerate the higher
dose with clinically acceptable toxicities. All patients who
received the study drug reported at least one treatment-
emergent adverse event (TEAE). Overall, 27 patients
(81.8%) reported at least one drug-related AE. The most
Figure 2 Kaplan-Meier probability curves for the efficacy variables including overall survival (A), progression-free survival (B),
time-to-treatment failure (C), and duration of response (D). Time-to-event outcomes are presented in months. CL Z confidence
limit; NC Z not calculable because the curve did not reach the specified percentile.
Table 2 Frequency of possible drug-related maximum
grade 3/4 CTCAE events.
Event classification Patients, N (%)
N Z 33
Hematological
Neutrophils/granulocytes 9 (27.3)
Leukocytes 8 (24.2)
Hemoglobin 5 (15.2)
Lymphopenia 5 (15.2)
Platelets 2 (6.1)
Pemetrexed in nonsmall cell lung cancer 523commonly reported drug-related AEs were fatigue (26
events), decreased leukocyte count (45 events), and
decreased neutrophil count (22 events). No deaths
occurred while receiving treatment or within 30 days of
receiving the last dose; 17 patients died after the 30-day
posttherapy follow-up phase. There were two drug-related
SAEs (neutropenia and leukopenia) and two drug-related
AEs (renal insufficiency and increased alanine amino-
transaminase levels) that resulted in discontinuation from
study treatment.
AEs with grade 3/4 toxicity were reported in 22 patients
(66.7%). Of these 22 grade 3/4 events, 16 events were
considered related to study treatment (Table 2). Decreased
neutrophil/granulocyte counts were the most frequently
observed grade 3/4 hematologic events (9 patients, 24
treatment cycles); all incidents were thought to be related
to the study drug. Fatigue was the only drug-related grade
3/4 nonlaboratory event (2 patients, 2 treatment cycles).Nonhematological
ALT 2 (6.1)
Fatigue 2 (6.1)
ALT Z alanine transaminase; CTCAE Z Common Terminology
Criteria for adverse events (version 3.0); N Z total number of
patients.Exploratory analyses
Univariate analyses were performed to relate the objec-
tive response rate to the histological classification (squa-
mous vs. nonsquamous). Of the 25 patients with
nonsquamous disease, six (24.0%), nine (36.0%), and eight(32.0%) demonstrated a partial response, stable disease,
or progressive disease, respectively. In comparison, of the
eight patients with squamous histology, none (0.0%), three
(37.5%), and three (37.5%) demonstrated a partial
response, stable disease, or progressive disease, respec-
tively. When compared with those in the squamous
524 G.-C. Chang et al.subgroup, patients in the nonsquamous subgroup demon-
strated a numerically higher objective response rate (24%
vs. 0%) and disease control rate (60% vs. 37.5%); however,
the differences did not reach a level of statistical signif-
icance (p > 0.05). These results were similar to the time-
to-event parameters. Sixteen (64.0%) patients with non-
squamous histology and six (75.0%) patients with squa-
mous histology demonstrated grade 3/4 CTCAE events
(p > 0.05). Other univariate analyses showed that there
was no statistically significant association between sex,
dose escalation, or smoking status in terms of the best
overall response or grade 3/4 CTCAE events (p > 0.05). In
addition, the potential pharmacogenomic associations
between dose escalation (i.e., received the 1000 mg/m2
dose in cycle 2) and grade 3/4 CTCAE events were inves-
tigated by determining the white blood cell TS poly-
morphisms. Of the 21 patients with the 3R/3R TS
genotype, 19 patients received the 1000 mg/m2 dose in
cycle 2 and 13 patients experienced a grade 3/4 CTCAE
event. Of the remaining 10 patients (i.e., 9 patients with
the 2R/3R TS genotype and 1 patient with the 2R/2R TS
genotype), five patients received the 1000 mg/m2 dose in
cycle 2 and seven patients experienced a grade 3/4 CTCAE
event. Given the small sample size, no statistical analyses
were conducted.Discussion
To the best of our knowledge, this was the first study on the
use of second-line pemetrexed for treating Taiwanese
patients with advanced NSCLC and failure to prior systemic
chemotherapy. At the moment of study designed in 2006,
the high dose concept of pemetrexed in the second line
treatment was evaluated in several studies, including
1000mg/m2 in Japan pivotal study (Alias: H3E-JE-NS01,
NCT00191191) and 900mg/m2 in Western population study
(Alias: H3E-MC-JMGX, NCT00078260). That is why the
escalated dose design was carried out in this study. While
the standard dose of pemetrexed remains 500 mg/m2
afterward, this study demonstrated that the majority of
patients are able to receive and tolerate an increased dose
of 1000 mg/m2 in cycle 2. These findings support the use of
second-line pemetrexed for treating Taiwanese patients
with advanced NSCLC.
Overall, the objective response rate and time-to-event
measures with pemetrexed obtained in this study are
consistent with those reported in the literature for both
Asian18 and Western7,12 populations. Nevertheless,
differences in the study designs and study populations
limit the ability to compare findings across studies. Our
study was not designed to determine which dose of
pemetrexed had greater efficacy. However, since this
study was conducted, two randomized controlled trials
have demonstrated that dose escalation beyond 500 mg/
m2 does not result in improved efficacy. In a phase II
randomized study of two doses of pemetrexed (500 mg/m2
vs. 1000 mg/m2) that were administered to pretreated
Japanese patients, there were no significant differences
between the dose groups in terms of the objective
response rate (18.5% and 14.8% for the 500 mg/m2 and
1000 mg/m2 doses, respectively) or the duration ofresponse.18 In addition, a phase III randomized study of
second-line pemetrexed (500 mg/m2 vs. 900 mg/m2)
demonstrated that there were no statistically significant
differences between the dose groups in terms of the
objective response rate (7.1% and 4.3% for the 500 mg/m2
and 900 mg/m2 doses, respectively), median overall
survival, or progression-free survival.12
The clinically acceptable tolerability profile of second-
line pemetrexed, despite the majority of patients
receiving the increased dose of 1000 mg/m2 in cycle 2, was
a major finding of our study. This observation is consistent
with the findings of other studies on the use of higher-dose
pemetrexed in Asian populations18,19 and may be a result
of the genetic disposition of these patients. Poly-
morphisms that result in higher TS expression may be more
common among East Asian populations20 and may account
for the improved tolerability to chemotherapy regi-
mens.21,22 To further identify which patients may benefit
from pemetrexed therapy, we performed a small phar-
macogenomic study to assess the relationship between TS
and MTHFR polymorphisms in white blood cell DNA (Table
1) and the response to pemetrexed treatment. However,
due to the small sample size, no inferential statistical
analyses could be performed. Therefore, we suggest that
the relationship between TS and MTHFR polymorphisms
and improved tolerability to chemotherapy be evaluated
in large randomized studies. In addition, supplementation
with folic acid and vitamin B12, which is mandatory in
Taiwan and has been shown to improve the toxicity profile
of second-line pemetrexed therapy,7,23 may at least in
part account for the improved tolerability to high-dose
pemetrexed.
The ability to predict which patients will respond to
specific chemotherapy regimens is an unmet clinical need.
Evidence from other studies on second-line pemetrexed,
performed on both Japanese18 and Western populations,12
suggests several prognostic factors that affect survival,
including histology, sex, disease stage, ECOG performance
status, and time since the last chemotherapy treatment. In
our study, we conducted an exploratory analysis in an
attempt to identify which prognostic factors (i.e.,
histology, smoking status, dose escalation, and sex) were
associated with the response to pemetrexed therapy in
Taiwanese patients. Though there were numerically more
patients who exhibited the best overall response in the
nonsquamous subgroup than the squamous subgroup, this
comparison was not statistically significant. The numerical
differences between histological subgroups in this study are
consistent with previous pemetrexed studies on NSCLC.24
This highlights the importance of appropriately tailoring
treatment based on patient and tumor characteristics,
though interpretation of our findings should take into
account the exploratory nature of these analyses and the
small sample size.
This study is limited by the low enrollment, small
sample size, and potential selection bias. The low enroll-
ment in this study can be explained by a number of
factors: (1) during study enrollment, alternative second-
line treatments for NSCLC, including oral epidermal
growth factor receptor inhibitors, such as gefitinib and
erlotinib, became commercially available and were reim-
bursed; (2) several competing second-line NSCLC trials
Pemetrexed in nonsmall cell lung cancer 525were being conducted in Taiwan during this period,
making it difficult to enroll patients into this study; and,
(3) at the time of study enrollment, two other studies
investigating dose escalation were published, neither of
which showed a benefit related to administering increased
doses.12,18 This was a single-arm study with a small sample
size; therefore, it is possible that selection bias is present
in this study. The inclusion criteria allowed for the
enrollment of patients with a performance status (PS) of
0 or 1 and stage IIIB and IV disease. Overall, most enrolled
patients had worse PS (72.7% PS 1 vs. 27.3% PS 0) and
advanced disease (90.9% stage IV vs. 9.1% stage IIIB).
Moreover, the median time from the last chemothera-
peutic failure to study entry was 0.9 months (range:
0.4e2.4 months). Taken together, these data suggest that
the patient population of this study had relatively more
progressive disease than may be found, on average, in the
general population of patients with NSCLC in Taiwan.
While a larger sample size may have afforded us the
opportunity to perform inferential statistics, through
which we could have assessed whether or not the data
from this study could be generalized to the wider patient
population, these data are similar to those reported in
other pemetrexed studies on NSCLC.7,12,18
In our study, the majority of patients received and
tolerated the 1000 mg/m2 dose in cycle 2. The efficacy and
tolerability data are consistent with the findings of other
pemetrexed studies on NSCLC, though interpretation of
these data is limited by the study design and the small
sample size. In conclusion, this study supports the use of
single-agent pemetrexed as a second-line treatment for
Taiwanese patients with advanced nonsquamous NSCLC.Role of the sponsor
Eli Lilly and Company (Indianapolis, IN) was involved in the
study design, data collection, data analysis, and prepara-
tion of the manuscript.Appendix I Criteria for pemetrexed dose escalation to 1000 m
Measure None of the followin
recorded at any time
Platelets <50  109/L
ANC <1.0  109/L
Stomatitis, pharyngitis, esophagitis,
or diarrhea
Grade > 2
Skin Grade > 2
Either 24-h urine creatinine clearance or
calculated creatinine clearance
NA
Serum bilirubin >3.0  ULN
AST or ALT >10  ULN
Alkaline phosphatase NA
Other nonhematological toxicities Grade > 2 (except n
ALT Z alanine aminotransferase; ANC Z absolute neutrophil count;
upper limit of normal.
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g toxicities
during cycle 1
Toxicity as recorded within 4 days
prior to the planned start date of cycle 2
100  109/L
1.5  109/L
Grade 0
Grade  1
45 mL/min
1.5  ULN
 3  ULNa
3 x ULNa
ausea, vomiting) Grade  1 (except alopecia)
AST Z aspartate aminotransferase; NA Z not applicable; ULN Z
r.
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